Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3285199 | 0.91 | CTSK (0.41) | CTSKMAPTADORA2AADORA2BAGTR1 | |
| SCHEMBL3286922 | 0.87 | — | — | |
| SCHEMBL3286678 | 0.81 | CTSK (0.35) | CTSKADORA2AADORA2B | |
| SCHEMBL3284453 | 0.79 | TNF (0.38) | CTSKMAPTLMNAMAPK1HTT | |
| SCHEMBL3844466 | 0.75 | — | — | |
| SCHEMBL3288381 | 0.74 | SCD (0.31) | — | |
| SCHEMBL3291203 | 0.72 | DPP4 (0.33) | LMNANPSR1 | |
| SCHEMBL3285814 | 0.71 | CTSK (0.60) | CTSKNPSR1ADORA2AADORA2B | |
| SCHEMBL3290916 | 0.69 | PDE4A (0.41) | MAPTADORA2AADORA2B | |
| SCHEMBL3285813 | 0.66 | ADORA2B (0.43) | LMNAMAPK1HTTNPSR1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713971-B2 | 1,2,4-triazine derivatives, preparation and use thereof in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2010-05-11 | — | — | US | disclosed |
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | PIERRE FABRE MEDICAMENT (FR) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | CBR3, NOX3, RTN3 | CTSK 4406/4885MAPT 4269/4885LMNA 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.